US Patent Issued to INSTITUT PASTEUR, SPIKIMM on April 22 for "Broadly SARS-CoV-2 neutralizing monoclonal antibodies and uses thereof" (French Inventors)

ALEXANDRIA, Va., June 6 -- United States Patent no. 12,281,155, issued on April 22, was assigned to INSTITUT PASTEUR (Paris) and SPIKIMM (Paris).

"Broadly SARS-CoV-2 neutralizing monoclonal antibodies and uses thereof" was invented by Antoine Pau (Paris), Hugo Mouquet (Paris) and Cyril Planchais (Paris).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-C...